Decline in FEV1 related to smoking status in individuals with severe α1-antitrypsin deficiency (PiZZ)

European Respiratory Journal

Volumn 13, Issue 2, 1999, Pages 247-251

  Piitulainen, E ^a,b   Eriksson, S ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

1 antitrypsin deficiency; Lung function decline; Smoking; Smoking cessation

Indexed keywords

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; DOSE RESPONSE; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; SPIROMETRY; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE;

ADULT; ALPHA 1-ANTITRYPSIN DEFICIENCY; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; SMOKING; SPIROMETRY;

EID: 0032586927     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.99.13224799     Document Type: Article

References (31)

1. 1-antitrypsin deficiency. Acta Med Scand 1965; 432 (Suppl.): 1-85.
2. 1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978; 204: 345-351.
3. Silverman KE, Pierce JA, Province MA, Rao DC, Campbell EJ. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med 1989; 111: 982-991.
4. Propst A, Propst T, Öfner D, Feichtinger H, Judmaier G, Vogel W. Prognosis and life expectancy in alpha-1-antitrypsin deficiency and chronic liver disease. Scand J Gustroenterol 1995; 53: 1108-1112.
5. 1-antitrypsin deficiency. Q J Med 1996; 89: 599-611.
6. 1-antitrypsin deficiency (PiZZ). Thorax 1997; 52: 244-248.
7. Kerstjens HAM, Brand PLP, Postma DS. Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154: 5266-272.
8. Brandy ML, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha- 1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988; 138: 327-336.
9. Buist AS, Burrows B, Eriksson S, Mittman C, Wu M. The natural history of air-flow obstruction in PiZ emphysema. Am Rev Respir Dis 1983; 127 (Suppl.): s43-s50.
10. 1-antitrypsin deficiency. Lancet 1985; 1: 152-154.
11. Hutchinson DCS, Tobin MJ, Cooper D, Lowe D. Longitudinal studies in alpha-1-antitrypsin deficiency: a survey by the British Thoracic Society. In: Taylor JC, Mittman C, eds. Pulmonary Emphysema and Proteolysis. New York, Academic Press. 1987: pp. 7-15.
12. Wu Mc, Eriksson S. Lung function, smoking, and survival in severe alpha-1-antitrypsin deficiency, PiZZ. J Clin Epidemiol 1988; 41: 1157-1165.
13. 1-antitrypsin deficiency type PiZ. Am J Respir Crit Care Med 1995; 152: 1922-1925.
14. 1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294: 1316-1321.
15. 1-antitrypsin deficiency. Acta Paediatric 1994; 83: 1170-1173.
16. 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055-1062.
17. 1-antitrypsin deficiency? Eur Respir J 1997; 10: 2260-2263.
18. Hutchison DCS, Hughes MD. Alpha-1-antitrypsin replacement therapy: will its efficacy ever be proved? Eur Respir J 1997; 10: 2191-2193.
19. 1-antitrypsin deficiency. Chest 1997; 111: 394-403.
20. Quanjer PH. Standardized lung function testing. Report of the working party on standardization of lung function tests. European Community for Coal and Steel. Bull Eur Physiopathol Respir 1983; 19 (Suppl. 16): 1-95.
21. Berglund E, Birath G, Bjure J, et al. Spirometric studies in normal subjects. I. Forced expirograms in subjects between 7 and 70 years of age. Acta Med Scand 1963; 173: 185-191.
22. 1-antitrypsin by electrofocusing. Clin Chem 1982; 225: 219-225.
23. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 964-974.
24. Jennrich RI, Schluchter MD. Unbalanced repeated measures models with structured covariance matrices. Biometrics 1996; 42: 805-820.
25. Fletcher CM, Peto R, Tinker CM, Speizer FE. The natural history of chronic bronchitis and emphysema. An eight-year study of early chronic obstructive lung disease in working men in London. Oxford, Oxford University Press, 1976.
26. Tashkin DP, Clark VA, Coulson AH, et al. The UCLA population studies of chronic obstructive respiratory disease. VIII. Effects of smoking cessation on lung function: a prospective study of a free-living population. Am Rev Respir Dis 1984; 130: 707-715.
27. Anthonisen NR, Connett JE, Altose MD, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
28. Postma DS, Sluiter HJ. Prognosis of chronic obstructive pulmonary disease: the Dutch experience. Am Rev Respir Dis 1989; 140: S100-S105.
29. Burrows B. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317: 1309-1314.
30. 1-antitrypsin deficiency. Thorax 1994; 49: 695-698.
31. 1-antitrypsin deficiency. Am J Respir Crit Care Med 1995; 151: 369-373.